

# Heparins in Thrombosis and Cancer

## Citation for published version (APA):

Vignoli, A. V. (2018). *Heparins in Thrombosis and Cancer: Effects on the Vascular Endothelium*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20181116av>

## Document status and date:

Published: 01/01/2018

## DOI:

[10.26481/dis.20181116av](https://doi.org/10.26481/dis.20181116av)

## Document Version:

Publisher's PDF, also known as Version of record

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

# Valorisation

Cancer patients are at high risk of developing venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism.

Indeed, in cancer patients VTE represents the second cause of death after the tumor itself, and significantly worsens their morbidity and the quality of life.

It is now well established that while the presence of a tumor predisposes the onset of VTE in the host, the activation of the hemostatic system in cancer may have a role not only in thrombosis but also in tumor growth and dissemination.

The effort of the current research aims to find valuable tools able to break down this mutual, vicious relationship.

In this respect, heparins, particularly the low molecular weight (LMWH) subcategory, are good candidates in that not only they are the drug of choice for the prophylaxis and treatment of VTE in a wide spectrum of pathological settings, including cancer, but they also appear to be endowed with direct and indirect anti-tumor features.

This has led to the development of a number of prospective randomized clinical trials to test LMWH to improve cancer survival as a primary end-point in cancer patients. Although the results are controversial, the interest in this research area remains high. Given the potential benefit of increased survival in oftentimes still fatal disease, any benefit, even small effects, may be clinically relevant. Therefore, it makes sense to dig deeper into the biology of cancer cells and to

better establish the effects of different types of heparins, on growth and proliferation of tumor cells.

We choose to study the impact of heparins on the vascular endothelium, this because endothelial cells play multiple roles in several patho-physiological processes, including hemostatic activation and cancer progression, so they appear an ideal target when you aim to impair the cancer/thrombosis association.

We could demonstrate that heparins may prevent the pro-thrombotic switch of the endothelial cells when exposed to tumor-derived products, as well as standard cytokines. This is relevant because the inhibition of fibrin formation has been considered a possible tool against the progression of malignant disease.

Endothelial cells take also part in tumor-driven angiogenesis. We could observe that heparins are able to impair the tumor-induced formation of capillary-like tubules (a key step in the neo-angiogenesis process) by endothelial cells in the well-known matrigel-based model. By counteracting the formation of new blood vessels, one could limit the tumor growth.

Then, we showed that heparins are able to counteract the direct adhesion of tumor cells to the vascular endothelium monolayer, by employing leukemic cells (but data are ongoing also with cells from solid tumor). This has important implications in that this effect may prevent tumor dissemination. We also showed that heparins counteract the

migration of cells from pancreatic cancer, a very aggressive subtype of cancer.

It has to be noted that we employed only cells of human origin, with regard to both endothelium and tumor. In particular, we used in all studies endothelial cells of the microcirculation, the most involved type in the pathological conditions, while the majority of published studies with the vascular endothelium have utilized cells from the macrocirculation.

Moreover, in our studies, we used not only the classical unfractionated heparin (UFH) and various types of LMWH, but also one representative of the very new ultra-low molecular weight heparin (ULMWH) subclass, i.e. RO-14. These newest heparins are characterized by a lower mean MW, and a more defined composition of polysaccharidic chain content. They are also characterized with a high anti-FXa activity and only residual anti-FIIa activity, thus the ratio anti-FXa/anti-FIIa is much greater compared to classical LMWH [1], that means that they should be endowed with a better efficacy/risk ratio compared to LWMH. Some ultra-LMWH are in clinical development [1-2]. However, little is known about their anti-cancer effects. Indeed, we first describe here that one of these ultra-LMWH i.e. RO-14 possess an anti-angiogenic activity similar to those shown by LMWH [3]. RO-14 also possesses a direct inhibitory effect on the migration of the pancreatic cancer cells.

With all the limitations coming from being *in vitro* studies, taken together these data further contribute to support the evidence of a possible *in vivo* anti-tumor effect of LMWH.

They also provide ground for future extensive studies, both in animal models and in clinical trials, about a possible role for LMWH and ULMWH in the cancer/thrombosis setting.

In summary, the potential therapeutic benefit of heparin derivatives for patients with malignant disease, is still out of reach. This does not mean that the promising findings from *in vitro* and animal studies could not translate into effective therapies. The use of specific fractions, such as non-anticoagulant heparins with reduced bleeding potential, and the application of better experimental models of disease, should be able to advance our knowledge. This gain in knowledge should translate into feasible focused clinical trials in highly selected patients with cancer, as to obtain proof of principle data on efficacy and mechanisms of action. The use of biomarkers, both for cancer cell death, as well as for vascular damage, hypercoagulability and other markers of vascular disease related to cancer, should help to explore the underlying mechanisms further.

## References

[1] Z. Liu, S. Ji, J. Sheng, F. Wang, Pharmacological effects and clinical applications of ultra low molecular weight heparins, *Drug Discov Ther* 8(1) (2014) 1-10.

[2] G. Agnelli, D.J. George, A.K. Kakkar, W. Fisher, M.R. Lassen, P. Mismetti, P. Mouret, U. Chaudhari, F. Lawson, A.G. Turpie, Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer, *N Engl J Med* 366(7) (2012) 601-9.

[3] A. Vignoli, M. Marchetti, L. Russo, E. Cantalino, E. Diani, G. Bonacina, A. Falanga, LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells, *Cancer Invest* 29(2) (2011) 153-61.